Illumina, Inc. (NASDAQ:ILMN) Given Average Recommendation of "Moderate Buy" by Brokerages

Shares of Illumina, Inc. (NASDAQ:ILMN - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the twenty-one ratings firms that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, eight have given a hold recommendation, ten have given a buy recommendation and two have given a strong buy recommendation to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $159.45.

Several equities research analysts recently issued reports on ILMN shares. Morgan Stanley reduced their price objective on Illumina from $150.00 to $136.00 and set an "equal weight" rating for the company in a research note on Tuesday, February 11th. UBS Group upped their target price on Illumina from $133.00 to $145.00 and gave the stock a "neutral" rating in a research report on Tuesday, November 5th. TD Cowen lowered Illumina from a "buy" rating to a "hold" rating and dropped their target price for the stock from $177.00 to $140.00 in a research report on Friday, February 7th. Robert W. Baird upped their target price on Illumina from $124.00 to $139.00 and gave the stock a "neutral" rating in a research report on Wednesday, November 6th. Finally, JPMorgan Chase & Co. upped their target price on Illumina from $125.00 to $140.00 and gave the stock a "neutral" rating in a research report on Tuesday, November 5th.

Institutional Trading of Illumina

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Versant Capital Management Inc lifted its position in shares of Illumina by 153.7% in the 4th quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company's stock worth $32,000 after acquiring an additional 146 shares during the period. Golden State Wealth Management LLC bought a new stake in shares of Illumina in the 4th quarter worth approximately $32,000. Assetmark Inc. lifted its position in shares of Illumina by 954.8% in the 4th quarter. Assetmark Inc. now owns 327 shares of the life sciences company's stock worth $44,000 after acquiring an additional 296 shares during the period. Bank Julius Baer & Co. Ltd Zurich bought a new stake in shares of Illumina in the 4th quarter worth approximately $45,000. Finally, Lee Danner & Bass Inc. bought a new stake in shares of Illumina in the 4th quarter worth approximately $48,000. Institutional investors and hedge funds own 89.42% of the company's stock.

Illumina Stock Down 1.5 %

Illumina stock traded down $1.54 during mid-day trading on Friday, hitting $100.24. The company's stock had a trading volume of 3,135,782 shares, compared to its average volume of 1,850,528. The firm's 50 day moving average is $132.74 and its 200 day moving average is $134.91. The company has a market cap of $15.90 billion, a PE ratio of -13.05 and a beta of 1.10. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.43 and a quick ratio of 1.85. Illumina has a 52-week low of $99.35 and a 52-week high of $156.66.

Illumina (NASDAQ:ILMN - Get Free Report) last announced its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a positive return on equity of 12.59% and a negative net margin of 27.95%. On average, analysts anticipate that Illumina will post 4.42 earnings per share for the current year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.